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CLINICIAN REPORTED OUTCOMES: ISSUES IN THE TRANSLATION 
AND LINGUISTIC VALIDATION
Furtado T, Wild D
Oxford Outcomes Ltd, Oxford, Oxon, UK
OBJECTIVES: The use of Clinician Reported Outcomes (ClinROs) and cognitive 
functioning measures in multi-national clinical trials is widespread, but the translation 
of such measures has often been avoided, with trial managers preferring to keep the 
measures in English. However, this approach is not ideal and recently the importance 
of translating and linguistically validating ClinROs has been highlighted. The require-
ments for translating and linguistically validating ClinROs have not been well docu-
mented. Usually, they are translated with a PRO translation procedure (comprising 
dual forward and back translations and subsequent review) with the addition of a 
single clinician review. This study investigates the issues surrounding the translation 
and linguistic validation of these ClinROs and cognitive functioning measures. 
METHODS: A review was undertaken of translation reports from past projects, 
including the MMSE and SCID (cognitive functioning measures), TNSN (clinician or 
nurse guide for assessing neuropathy) 6 Minute Walk Test (6MWT) Worksheet, (guide 
for clinicians to assess dyspnoea), and EORTC clinician scales. Examples of issues 
from the translation process were gathered. RESULTS: Clinical review as part of the 
translation process proved invaluable. Changes typically comprised alterations of 
speciﬁ c terminology.—a clinician should also be available to aid project coordinators 
throughout the translation process.—Clinical review formed an essential role for 
advising lead translators.—One project included dual clinician reviews; this was par-
ticularly valuable since changes could be veriﬁ ed between reviewers. CONCLUSIONS: 
The translation and linguistic validation of ClinROs and cognitive functioning mea-
sures requires further research to determine the optimum methodology. This study 
found that clinical review was of the utmost importance, and that ideally dual clinician 
reviewers should be involved. Furthermore, translators should have experience of 
translating documents intended for clinical use, to ensure they are familiar with the 
terminology.
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USING DOZENS OF ATTRIBUTES WITHOUT INCREASING 
RESPONDENT BURDEN: HOW TO ADAPT LATENT VARIABLE 
MODELING FOR LINKING ATTRIBUTES ON SEPARATE CONJOINT 
SURVEYS
Cole JC1, Dang J2
1Covance Market Access Services, San Diego, CA, USA; 2University of California, Los 
Angeles, Torrance, CA, USA
Conjoint analysis is a rigorous survey technique used to understand health care prefer-
ences in the pharmaceutical and medical device industries. In a traditional conjoint 
study, respondents are presented with a complete proﬁ le of all of the combination of 
attributes and features (or levels) for a particular product or service. However, 
research involving a large number of attributes can be too burdensome for respondents 
and has been shown to elicit inaccurate responses. This study describes a procedure 
used to link attributes from two or more different conjoint surveys that share at least 
one attribute. Linked latent conjoint modeling can lessen the burden on respondents 
while allowing utility parameters to be estimated for a large number of attributes, all 
on the same interval scale. Conjoint survey data were linked using a partial proﬁ le 
design and parameters were calculated using maximum likelihood estimation for ﬁ nite 
mixture modeling. Several examples demonstrating the procedures used to link choice 
based survey data are provided. In addition, results from a latent variable modeling 
of the linked survey data are reviewed. Finally, to illustrate the ﬂ exibility of latent 
conjoint analysis, continuous and categorical covariates were simultaneously esti-
mated to demonstrate the usefulness of latent modeling of conjoint data.
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COGNITIVE DEBRIEFING METHODS IN TRANSLATION OF PROS: A 
MULTI-NATIONAL
Furtado T, Gergovich KB, Wild D
Oxford Outcomes Ltd, Oxford, Oxon, UK
OBJECTIVES: Cognitive debrieﬁ ng interviews are a key component of the translation 
and linguistic validation of PROs and a necessity when a PRO is to be used as a 
primary or secondary endpoint for an FDA label claim. The 2005 ISPOR principles 
of good practice report describes the objectives of debrieﬁ ng, but little discussion has 
been undertaken into the methods for performing debrieﬁ ng interviews as part of the 
translation and linguistic validation process. This abstract presents a pilot test of 
methodologies across countries. METHODS: A literature review was conducted on 
cognitive debrieﬁ ng methodology, and different approaches were pilot tested in 10 
countries. Three methodologies were selected for pilot testing: 1) Retrospective 
probing 2) Retrospective think aloud 3) Concurrent think aloud. RESULTS: The lit-
erature review highlighted the methodologies and pros and cons of different 
approaches to cognitive debrieﬁ ng, but no research was identiﬁ ed that addressed the 
issues of particular relevance in the translation and linguistic validation process. All 
three processes listed above proved suitable for a methodology for linguistic valida-
tion. The Think Aloud technique provided a true sense of the respondent’s understand-
ing of the translation but its suitability was particularly subject to cultural and 
individual differences. Questionnaires of a personal nature (e.g. those pertaining to 
sex or bowel disorders) beneﬁ ted from Retrospective Probing, since the patients could 
respond hypothetically. The Retrospective Think Aloud technique elicited more infor-
mation from some respondents, since it allowed them to discuss their personal experi-
ence. Where the respondent had difﬁ culty in understanding what was required of 
them, modifying the interview style proved beneﬁ cial. CONCLUSIONS: A combina-
tion of Retrospective Probing and Retrospective Think Aloud proved to be the 
optimum methodology across countries, but this was dependent on the culture, 
patient, and the nature of the PRO being translated.
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CONSTRUCTION OF PRIMARY HUI3 PERSON-MEAN UTILITY SCORING 
FUNCTION
Furlong W1, Feeny D2, Torrance G3
1Health Utilities Inc., Dundas, ON, Canada; 2Kaiser Permanente Center for Health Research, 
Portland, OR, USA; 3McMaster University, Toronto, ON, Canada
OBJECTIVES: To assess construction of the primary HUI3 scoring system. 
METHODS: Mean visual analogue scale (VAS) and standard gamble (SG) scores were 
collected in 2 face-to-face interview surveys: modeling survey (MS) for the Person-
Mean utility scoring model to calculate community utilities for health states; direct 
survey (DS) for validation of the Person-Mean scoring model. Survey results are 
assessed for completeness and consistency. Completeness is evaluated by response 
rates and consistency by health state rankings. RESULTS: Completed interviews were 
obtained from 65% of contacted eligible subjects. Demographic distributions are 
similar to the underlying general population. There are 256 respondents in MS and 
248 in DS. MS and DS respondents use 71% of HUI3 attribute levels in describing 
their own health status. Each of the 8 HUI3 attributes are reported by 35 or more 
respondents as being important in their preference measurements: pain (49%); vision 
(37%); cognition (34%); emotion (28%); ambulation (28%); hearing (17%); dexterity 
(17%); speech (7%). More than 70% of respondents focused on 2+ attributes. Other 
important preference measurement factors are self-care ability (89% of respondents), 
family life (76%), happiness of others (69%), ability to work current job (61%), 
leisure activities (42%). 83% of respondents report the interviewing did not change 
their opinions about the health states. Consistency of health state rankings by mean 
VAS and SG scores between MS and DS was 100%: PH > MA > MB > MC > Dead 
> Pits. MS had a missing data rate of 0.29% (17/5920) for VAS and 0.10% (1/1024) 
for SG. CONCLUSIONS: The Person-Mean HUI3 utility function is founded on a 
survey that was well-constructed in terms of community and attribute representation, 
consideration of multiple attributes and day-to-day impacts, stable opinions, and 
consistency of health state rankings. This evidence supports use of the primary HUI3 
utility function for group-level analyses, such as allocation of societal resources.
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MINIMALLY IMPORTANT DIFFERENCE OF THE TREATMENT 
SATISFACTION WITH MEDICINES QUESTIONNAIRE (SATMED-Q)
Rejas J1, Ruiz MA2, Pardo A2, Soto J1
1Pﬁ zer España, Alcobendas/Madrid, Spain; 2Universidad Autonoma de Madrid, Madrid, Spain
OBJECTIVES: Treatment satisfaction with drug therapies is an important patient-
reported-outcome (PRO) that may help clinicians to better impact in patient health 
care. The Treatment Satisfaction with Medicines (SATMED-Q) questionnaire has 
shown appropriate psychometric properties for exploring patient’s satisfaction with 
medicines under routine medical practice in chronic health conditions. The Minimally 
Important Difference (MID) of the instrument is still unknown. The goal of this 
research was to determine the MID values of the SATMED-Q questionnaire for the 
total score and domains. METHODS: The sample of patients (457, mean age 59 years, 
53% male) used for testing psychometric properties was also used to assess MID 
values. Item #14 of the TSQM scale was used as an anchor reference, since it explores 
directly the satisfaction with medicines in a seven points ordinal response (from 
extremely satisﬁ ed to extremely dissatisﬁ ed). Patients were classiﬁ ed into four catego-
ries according with responses in this item; extremely satisﬁ ed/dissatisﬁ ed, very satis-
ﬁ ed/dissatisﬁ ed, satisﬁ ed/dissatisﬁ ed, nor satisﬁ ed/nor dissatisﬁ ed and comparisons 
were carried out for the overall score and each domain of the SATMED-Q using 
standardized scores. The mean differences in overall score (and domains) between the 
neutral category and the satisﬁ ed/dissatisﬁ ed category were considered the values of 
MID. Effect sizes (ES) were also computed. RESULTS: MID for total scoring was 13.4 
(ES = 0.91), while the value for domains ranged from 10.3 (medical care domain, ES 
= 0.43) to 20.6 (impact of daily living, ES = 0.85). Mean score differences in overall 
scale and domains were signiﬁ cant between change in satisfaction categories with 
respect item#14 with F values ranging from 9.7 to 74.1 (P < 0.001 in all cases). 
CONCLUSIONS: The SATMED-Q demonstrated to be responsive to different levels 
of patient’s satisfaction with therapy in chronically ill subjects. Attained MID was 
13.4 pts for the overall normalized scoring scale and between 10.3 and 20.6 pts for 
domains.
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ESTIMATING HEALTH STATE UTILITY VALUES FOR COMORBID 
HEALTH CONDITIONS
Ara R, Brazier J
University of Shefﬁ eld, Shefﬁ eld, UK
OBJECTIVES: Health state utility values (HSUVs) for comorbid health conditions 
(CHC) are frequently estimated using data from single health conditions but there is 
no consensus on the most appropriate method. The objective of the study is to compar-
ing ﬁ ve techniques in a single data set. METHODS: We use EQ-5D data from the 
Health Survey for England to compare results generated using the: additive, multiplica-
tive and minimum methods, the adjusted decrement estimator (ADE), and a linear 
regression model; a baseline of perfect health and an adjusted baseline obtained from 
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individuals who indicate they have no chronic health condition. Results are compared 
using mean errors (ME), root mean squared errors (RMSE) and the proportion of 
values estimated within |0.05|. RESULTS: Using an age adjusted baseline, we found 
the additive (and multiplicative) methods underestimate the majority of HSUVs 
(ME:0.0781(0.0254); RMSE:0.1012(0.0651); 26%(56%) < |0.05|) while the minimum 
(and ADE) overestimate the majority of HSUVs (ME:−0.0995(−0.0695); 
RMSE:0.1214(0.0950); 20%(35%) < |0.05|). Although the simple linear model pro-
duced the most accurate results (ME:0.0001; RMSE:0.0598; 63% < |0.05|), there were 
some substantial errors with 20% of errors greater than the minimum important 
difference (|0.074|). When subgrouping by actual HSUV (range 0.350–0.917) we 
found the magnitude and direction of errors in the estimated HSUVs are driven by 
the actual HSUVs being estimated in addition to the technique used. In general the 
HSUVs estimated using an adjusted baseline were more accurate than those obtained 
using a baseline of perfect health. CONCLUSIONS: This study makes an important 
contribution to the evidence in this area as it is the ﬁ rst to compare the ﬁ ve different 
techniques in the same data set. While the simple linear model gave the most accurate 
results, the model requires validating in external data and additional research explor-
ing an alternative model speciﬁ cation is warranted.
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ISSUES IN THE TRANSLATION AND LINGUISTIC VALIDATION OF 
CAREGIVER RATING SCALES REGARDING THE BEHAVIOR AND 
DEVELOPMENT OF CHILDREN AND YOUNG PEOPLE
Furtado T, Wild D
Oxford Outcomes Ltd, Oxford, Oxon, UK
OBJECTIVES: Caregiver rating scales, intended to evaluate the behaviour of children 
and young people, are frequently used in clinical trials involving youths. However, the 
translation and linguistic validation of such scales can be problematic due to the differing 
cultural markers of behaviour and development. This study aims to document the 
problems that can occur, with the hope of facilitating future studies and producing 
guidelines to avoid cultural compromises when such measures are developed. 
METHODS: Past Oxford Outcomes projects, which included the translation of Care-
giver Reported Outcomes, were evaluated to identify problematic items. These included 
the Vineland-II and ABAS (behaviour development scales), ELDQOL (epilepsy and QoL 
scale) and WFI-RS (functional impairment rating scale) among others. RESULTS: 
Numerous cultural and linguistic issues became apparent, including the following:—
Many examples of sports and activities were used in the documents, which required 
thorough cultural adaptation, e.g. types of games.—Logistical cultural differences were 
marked, e.g. questionnaires mentioned children’s understanding of speciﬁ c coins or 
trafﬁ c signals, which vary culturally.—Some documents involved markers for identifying 
speech development, such correct use of irregular verbs. These were problematic in other 
cultures and speech development specialists were required to ﬁ nd suitable alternatives.—
More idiomatic expressions are used than in PROs developed for adults, e.g. “on the 
go”; these cause difﬁ culties in translation.—Items surrounding activities such as house-
work or helping look after siblings are not equivalent in some cultures due to differing 
role expectations. CONCLUSIONS: The validation of caregiver reported outcomes 
through interviews with caregivers was particularly important with these scales to ensure 
cultural appropriateness in target languages. Physician or specialist input was sometimes 
required to ﬁ nd culturally relevant alternatives. When such measures are created, cultur-
ally speciﬁ c markers of behaviour should be avoided if possible.
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RECOMMENDATIONS ABOUT TRANSLATIONS IN THE FINAL FDA 
GUIDANCE ON PRO MEASURES: WHAT HAS CHANGED AND WHAT 
HAS REMAINED
Conway K1, Mear I2
1MAPI Research Trust, Lyon, France; 2MAPI Institute, Lyon, France
OBJECTIVES: Almost four years were necessary to develop the ﬁ nal FDA guidance 
on the use of PRO measures in clinical trials. Our objective is to compare how the 
recommendations about translation and cultural adaptation evolved from the 2006 
draft to the 2009 ﬁ nal guidance. METHODS: Both guidances were retrieved on the 
FDA website and analyzed. RESULTS: Structure and content were modiﬁ ed. Recom-
mendations on translation and cultural adaptation were moved to another section 
within the Evaluating PRO Instruments Part: from “IV.D. Modiﬁ cation of an existing 
instrument” to “III.G. PRO Instruments intended for speciﬁ c populations”. As for 
the content, the text in the body of the ﬁ nal guidance is more concise compared to 
the draft. The novelty lies in the stipulation that the FDA will review the process used 
to translate/culturally adapt the instruments. As a consequence, an appendix (section 
VIII) was added in which the FDA explains which topics should be addressed in the 
documents provided to the FDA for review: description of process used, patient 
testing, rationale for decisions, copies of versions and evidence about validity. They 
are however key points which did not change: the need for providing evidence that 
content validity and other measurement properties are similar between all versions. 
CONCLUSIONS: The recommendations are more concise and precise, especially the 
expectations of the FDA. The FDA however does not indicate a preference for a 
speciﬁ c translation methodology. Interestingly patient testing is clearly indicated as a 
key point of the process. The need for documenting all decisions is crucial and raises 
the question of developing standardized system of reporting to structure the evidence 
to be provided to the FDA. The last point of the Appendix is debatable as we anticipate 
that it might add a burden in term of costs to provide evidence about the psychometrics 
of all versions.
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SYSTEMATIC REVIEW OF THE RESPONSIVNESS OF SF-36 HEALTH 
SURVEY MEASURES TO EFFICACIOUS PHARMACEUTICAL THERAPIES 
IN WELL-CONTROLLED CLINICAL TRIALS
Ware JE, Frendl DM
University of Massachusetts, Worcester, MA, USA
OBJECTIVES: To determine how often SF-36 Health Survey measures respond to 
efﬁ cacious pharmaceutical treatment beneﬁ ts in well-controlled clinical trials. 
METHODS: We conducted a systematic review of randomized, double-blind, placebo-
controlled trials published in 124 journals in 1995 through 2009 documenting differ-
ences between treatment groups for primary medical endpoints and any of the SF-36 
component summaries, or eight subscale scores. Concordance was deﬁ ned in terms of 
agreement between primary clinical and SF-36 endpoints (both statistically signiﬁ cant 
or both non-signiﬁ cant). RESULTS: A review of 2,020 identiﬁ ed clinical trials using 
the SF-36 conﬁ rmed that 162 met study design criteria. For 133 of 162 trials (82.1%), 
results for primary clinical endpoints and SF-36 measures were concordant. Among 
the 107 trials achieving medical efﬁ cacy (primary endpoint), changes in one or more 
SF-36 measures were also signiﬁ cant, as hypothesized, for 88 (82.2%). Similar patterns 
were observed by therapeutic area; for example: rheumatology (29 of 30), neurology 
(16 of 25), cardiovascular (15 of 18), pulmonary (11 of 13), psychiatry (8 of 10), 
endocrine (7 of 9), and combined surgical specialties (9 of 9) studies demonstrated 
concordance. In addition to evaluating characteristics of published reports and scoring 
methods (subscales, summaries, utility scoring) this presentation will comment on 
priorities for future studies of patient-reported outcomes (PROs) in evaluations of 
pharmaceutical and other medical treatments. CONCLUSIONS: In support of their 
validity as PROs, changes in SF-36 measurements agree with primary endpoints in 
over 8 out of 10 well-controlled trials of pharmaceutical therapies published to date. 
In support of pharmaceuticals’ efﬁ cacy, when a therapy positively impacted clinical 
endpoints, it also improved health related quality of life quality of life in over 8 out 
of 10 clinical trials published to date.
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DOES DATA COLLECTION FROM ONLINE COMMUNITIES RESULT IN 
BIASED RESPONSE?
Vaccarino AL1, Sills TL1, Bharmal M2, Cascade E3, Kalali AH4, Evans KR1
1OCBN, Toronto, ON, Canada; 2Quintiles, Rockville, MD, USA; 3iGUARD Inc, Rockville, 
MD, USA; 4Quintiles CNS Therapeutics, San Diego, CA, USA
OBJECTIVES: Although the ability to interact with patients in an on-line environment 
has expanded substantially over the past few years, many researchers are concerned 
that participants may not be representative from a medication experience perspective 
(i.e., biased towards complainers). The purpose of this study is to investigate patient 
responses on treatment satisfaction using a validated PRO measure, the Treatment 
Satisfaction Questionnaire for Medications (TSQM), collected through a survey of 
patients with depression from an on-line community. METHODS: A random sample 
of iGuard.org members treated with an antidepressant were invited to complete an 
online version of the TSQM, a widely used validated 14-item generic treatment satis-
faction instrument. iGuard.org is an online patient community that provides a free 
medication monitoring service to patients. Non-parametric item response analyses 
were performed to determine the relationship between scores on individual items and 
total TSQM scores. RESULTS: Responses from 3641 patients were included in the 
analyses. TSQM Global Satisfaction scores ranged from 0—100 suggesting a broad 
spectrum of treatment satisfaction. Non-parametric Item Response analyses of raw 
scores revealed that individual items of the TSQM discriminated differences in patient 
satisfaction. That is, as total scores increased the probability of low scores on the 
individual items decreased and the probability of higher scores increased. As expected, 
patient satisfaction was related to reported side-effects, with those reporting side-
effects experiencing lower satisfaction with medication than those without reported 
side-effects. CONCLUSIONS: The results from this analysis suggest that PRO survey 
data collected through a random sample of members of the on-line patient community 
iGuard.org can be representative of the spectrum of anticipated treatment satisfaction 
responses. Continuing to explore the potential of direct data capture from on-line 
patients will be important as researchers seek faster and cheaper alternatives to tradi-
tional physician-based recruitment.
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A COGNITIVE DEBRIEFING METHODOLOGY FOR ESTABLISHING 
EQUIVALENCE DURING E-PRO MIGRATION
Doyle S, Wild D
Oxford Outcomes Ltd, Oxford, Oxon, UK
BACKGROUND: Most outcomes instruments have been developed and validated as 
paper versions, but few have been migrated to electronic format. Migration to elec-
tronic delivery, without signiﬁ cantly altering format or text, qualiﬁ es as a minor 
modiﬁ cation not requiring a full validation (Coons et al. 2009). However, this does 
not mean that the two formats are perceived in the same way by patients. We aim 
here to describe a methodology successfully used to establish equivalence between 
paper and electronic PROs. METHODS: To demonstrate the equality of these differ-
ent modes of data collection, we have used a combination of “think-aloud” and ret-
rospective cognitive debrieﬁ ng techniques, as well as usability testing. The debrieﬁ ng 
exercise is designed to assess whether the electronic device changes the way respon-
dents interpret the questions or response options. The usability testing assesses 
ease of use and identiﬁ es issues that may prohibit the use of the ePRO by the target 
